Boehringer Ingelheim to Present 14 Abstracts at the Annual American Thoracic Society Internatio?nal Conference

Boehringer Ingelheim has announced that the first results from two highly anticipated Phase III trials in idiopathic pulmonary fibrosis (IPF) and in chronic obstructive pulmonary disease (COPD) will be presented at the 2014 American Thoracic Society (ATS) International Conference taking place 16–21 May in San Diego. In addition, 12 abstracts will be presented at the ATS International Conference. The extensive data being presented underscores the company's leadership in pioneering new drug therapies to treat serious lung diseases.

Key data being presented include results from the Phase III INPULSIS trials for nintedanib in the treatment of IPF. The initial results from the Phase III data for the fixed-dose combination tiotropium and olodaterol (T+O FDC) for COPD, Spiriva HandiHaler (tiotropium bromide inhalation powder) approved as a COPD maintenance treatment, as well as additional investigational treatments for asthma and COPD will also be presented.

"Building on our long-standing heritage and expertise in COPD, Boehringer Ingelheim is committed to expanding into other chronic respiratory diseases. We are particularly excited about our research on nintedanib for idiopathic pulmonary fibrosis, which is a rare, fatal disease with a significant unmet medical need," said Tunde Otulana, MD, senior vice president, Clinical Development and Medical Affairs at Boehringer Ingelheim. "The breadth of our data at this year's ATS annual meeting illustrates the depth of our commitment to developing therapies to treat serious lung diseases."

Nintedanib (Investigational)
Nintedanib is being investigated to determine its efficacy and safety in treating people with IPF. Its safety and efficacy have not been established and it is not approved.